Patient side cost and its predictors for cervical cancer in Ethiopia: A cross sectional hospital based study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Hailu, Alemayehu ^a   Mariam, Damen Haile ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

Cervical cancer; Cost of illness; Ethiopia; Human papilloma virus

Indexed keywords

ANTINEOPLASTIC AGENT;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER THERAPY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG COST; ETHIOPIA; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; OUTPATIENT; PATIENT SIDE COST; PREDICTION; PREVALENCE; PRODUCTIVITY; QUANTITATIVE STUDY; UTERINE CERVIX CANCER;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; ETHIOPIA; FEMALE; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMANS; INPATIENTS; LENGTH OF STAY; LINEAR MODELS; MIDDLE AGED; MODELS, ECONOMIC; SALARIES AND FRINGE BENEFITS; SICK LEAVE; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84873467413     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-69     Document Type: Article

References (29)

1. WHO: Comprehensive Cervical Cancer Control A guide to essential practice 2006, Switzerland: WHO Press, WHO: Comprehensive Cervical Cancer Control.
2. Anorlu RI. What is the significance of the HPV epidemic?. Can J Urol 2008, 15(1):3860-3865.
3. GLOBOCAN Cervical Cancer Incidence and Mortality Worldwide in 2008 2008, CANCER FACT SHEET, GLOBOCAN.
4. Castellsagué X, Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, et al. HPV and Cervical Cancer in the World. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2007,
5. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) Human Papillomavirus and Related Cancers in Ethiopia Summary Report 2010, WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre).
6. Aseffa A, Zein AZ. Neoplasms in Gondar. Ethiop Med J 1986, 24:133-136.
7. Loutfi A, Pickering IL. The distribution of cancer specimens from two pathology centers in Ethiopia. Ethiop Med J 1982, 30:13-17.
8. Ashine S, Lemma B. Malignant tumours at Yirga Alem hospital. Ethiop Med J 1999, 37:163-172.
9. Pelzer A, Duncan ME, Tibaux G, Mehari L. A study of cervical cancer in Ethiopian women. Cytopathology 1992, 3(3):139-148. 10.1111/j.1365-2303.1992.tb00039.x, 1511118.
10. Insinga RP, Dasbach EJ, Elbasha EH. Assesing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23(11):1107-1122. 10.2165/00019053-200523110-00004, 16277547.
11. Lipsy RJ. Assessing the short-term and long-term burden of illness in cervical cancer. Am J Manag Care 2008, 14(6 Suppl 1):S177-S184.
12. Gil A, San-Martin M, Gil R, Hernandez V, Ribes J, Gonzalez A. Burden of hospital admissions for cervical cancer in Spain during 1999-2002. Hum Vaccin 2007, 3(6):276-280.
13. Ben Gobrane H, Aounallah-Skhiri H, Oueslati F, Frikha H, Achour N, Hsairi M. Estimated cost of managing invasive cervical cancer in Tunisia. Sante Publique 2009, 21(6):561-569.
14. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic valuation of Health Care Programs 2005, Oxford: Oxford University Press, 3rd.
15. World Bank databese http://data.worldbank.org/indicator/PA.NUS.PPPC.RF (accessed: January 27, 2013, World Bank databese.
16. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70(2):209-262.
17. Tsu VD, Levin CE. Making the case for cervical cancer prevention: what about equity?. Reprod Health Matters 2008, 16(32):104-112. 10.1016/S0968-8080(08)32411-2, 19027628.
18. Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998, 34(12):1889-1893. 10.1016/S0959-8049(98)00232-9, 10023311.
19. Bhurgri Y, Nazir K, Shaheen Y, Usman A, Faridi N, Bhurgri H, et al. Patho-epidemiology of Cancer Cervix in Karachi South. Asian Pac J Cancer Prev 2007, 8(3):357-362.
20. Silvina A, Elena M, Nicolas Z, Berta R, Sankaranyananana R, Maxwell P. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherpay compliance. Results from a cross-sectional study. Gynacologyc Oncology 2007, 105:335-340.
21. Denny L. Prevention of cervical cancer. Reprod Health Matters 2008, 16(32):18-31. 10.1016/S0968-8080(08)32397-0, 19027619.
22. Ratinahirana S, Razanamparany PV, Razafintsalama B, Randriamampandry A, Ravaoarison J, Rabarijaona L, et al. 79 cases of invasive cancer of the cervix uteri in the Department of Oncology in Antananarivo. Can diagnostic delays be improved?. Sante 1995, 5(3):195-198.
23. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005, 294(17):2173-2181. 10.1001/jama.294.17.2173, 16264158.
24. Arveux P, Benard S, Bouee S, Lafuma A, Martin L, Cravello L, et al. Invasive cervical cancer treatment costs in France. Bull Cancer 2007, 94(2):219-224.
25. Issah F, Maree JE, Mwinituo PP. Expressions of cervical cancer-related signs and symptoms. Eur J Oncol Nurs 2011, 15(1):67-72. 10.1016/j.ejon.2010.06.003, 20673743.
26. Ashing-Giwa KT, Gonzalez P, Lim JW, Chung C, Paz B, Somlo G, et al. Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors. Cancer 2010, 116(13):3195-3204. 10.1002/cncr.25060, 20564623.
27. Charles L, Bennett A, Elizabeth A. Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study with Community Oncology Cancer Patients. Oncologist 2007, 12:478-483. 10.1634/theoncologist.12-4-478, 17470690.
28. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009, 20(4):417-435. 10.1007/s10552-008-9256-0, 2711979, 19002764.
29. Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 2005, 6(4):309-313. 10.1007/s10198-005-0303-4, 16133097.